(Alliance News) - GSK PLC on Wednesday said it reached two confidential settlements regarding the Zantac case in California State Court. The London-based pharmaceutical company said the cases ...
LONDON, UK I 12, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal ...
Shares of GSK PLC GSK inched down 0.34% to £16.04 Wednesday, on what proved to be an all-around rough trading session for the ...
LONDON, UK I 11, 2024 I GSK plc (LSE/NYSE: GSK) today announced that it has completed the primary objective data analysis from the phase II part of ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the ...
Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...
GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and ...
London open The FTSE 100 is expected to open 99 points higher on Thursday, having closed down 0.15% on Wednesday at 8,193.94.
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...
Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback